Arcellx Confirms All Regulatory Approvals Secured for Gilead Acquisition; Tender Offer Extended to April 27
ACLX has more than doubled off its 52-week low of $47.86 on light trading volume (0.2× avg).
Summary
Arcellx, Inc. filed an amendment confirming that all regulatory approvals for its acquisition by Gilead Sciences have been secured, and the tender offer has been extended to April 27, 2026.
Key Events · M&A and Partnerships · ACLX
-
All Regulatory Approvals Secured
Arcellx announced that all required regulatory approvals for the acquisition by Gilead Sciences have been obtained, including decisions from Australian and Austrian competition authorities. This satisfies a key condition for the merger's completion.
-
Tender Offer Extended
The tender offer by Gilead Sciences' subsidiary, Ravens Sub, Inc., has been extended until 5:00 p.m. Eastern Time on April 27, 2026. This extension is a procedural step to align with the expiration of the final regulatory waiting period.
-
Merger Imminent
With all regulatory conditions met, the Purchaser expects to consummate the offer promptly following the new expiration date, assuming the minimum tender condition and other offer conditions are satisfied or waived.
Analysis · ACLX · Life Sciences
This amendment significantly de-risks the pending acquisition of Arcellx by Gilead Sciences by confirming that all necessary regulatory approvals have been obtained. The satisfaction of this critical condition precedent paves the way for the merger to close, providing certainty for shareholders. The extension of the tender offer is a procedural step to allow for the expiration of the final waiting period, indicating the transaction is on track for completion.
At the time of this filing, ACLX was trading at $115.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $47.86 to $115.13. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.